The world might be facing turmoil and uncertainty — states that Novavax Inc. knows all too well — but today, the Gaithersburg biotech has reason to celebrate.
The company has reported positive results for its late-stage clinical trial of seasonal flu vaccine NanoFlu, marking its first successful phase 3 study after two devastating failures. These latest results now open an otherwise impenetrable door with a product candidate viewed as Novavax’s last best chance for success — and its first-ever commercial product in more than 30 years of operation.
{iframe}https://www.bizjournals.com/baltimore/news/2020/03/24/novavax-s-seasonal-flu-vaccine-just-got-great-news.html?ana=e_me_set1&j=90501362&t=Morning&mkt_tok=eyJpIjoiTm1NeFpUUXhZV1UzWldZNSIsInQiOiJaaVhwemM1SThlUG1vWUdkVE53YmpsZjZqSUZzMnlaWUVDUld6a255QW5DdWlzZnFjUkt0Uzc4a1VWank0XC9FREtVTndGM0dUUHMzeHJ5aHdOSEI1TVFsK3VsNkhIS2pLRW1HXC9udUFcL3d6ZjI1SVVKXC9TN0FCVno5amVhQVwvbXFlIn0%3D{/iframe}